Exam 2 drugs Flashcards
Lidocaine
Amide
fast onset, medium lipid solubility, medium potency, 64% protein bound
Topical, infiltration, nerve block, IV, Spinal, Epidural
Shorter duration than bupivacaine
Bupivacaine
Amide, High potency, medium onset, high lipid solubility, 95% protein bound
Particularly cardiotoxic
Infiltration, Nerve block, IV, Spinal, Epidural
Longer duration than lidocaine
Morphine
Opioid Phenanthrene
IV/IM and oral sustained release
Hydrocodone
Opioid Phenanthrene
Antitussive, weak analgesia
Oxycodone
Opioid Phenthrene
Equipotent to morphine
Codeine
Opioid Phenanthrene
Metabolized by CYP2D6
Less potent than morphine
High oral bioavailability
Tramadol
Opioid Phenanthrene
Acts at mu receptors
Also block monoamine uptake, potentiating descending pain pathway
Fentanyl
Phenylpiperidine
100x more potent than morphine
Short duration
Fast actng, no histamine release
Requires mechanical ventilation at high doses
IV, oral, transdermal
Buprenorphine
Benzomorphans
Partial mu agonist, can precipitate mild withdrawal
Can cause analgesia, can partially antagonize morphine
Long acting
Naloxone
Competitive antagonist
Short duration
No oral availability
Used to reverse overdose
Naproxen
NSAID
both peripheral and central (spinal)
Migraine-abortive
Celecoxib
COX-2 inhibitor
Both peripheral and central (spinal)
Increase risk of acrdiovascular complications such as MI (chronic use)
Acetaminophen
COX-2 inhibitor
CNS only
Oral, suppository, IV
Hepatotoxicity
Commonly added to opioids, no tolerance to hepatotoxicity
Migraine-abortive
Ketamine
NMDA blocker in ascending pain pathway
Can reduce development of tolerance to long-term opioid use
IV or intranasal
Side effects: hypertension, diplopia, dizziness, arrhythmias, nausea-vomiting, pschotomimetic reactions
Antidepressants
NE and 5-HT reuptake inhibitors
Central action
Enhancement of descending inhibitory pathway via PAG